In 1997, two independent groups: Stamey et al., and deKernion et al., detailed the first in-depth evaluations of postoperative PSA doubling times and their implications for early recurrence and, more importantly, for cancer aggressiveness and clinical progression [12,13]. This evidence concerns the gene KLK3 and cancer.